Blue Lake Biotechnology, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
A Study of BLB-201 RSV Vaccine in Infants and Children
Phase 1
Recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: PIV5-vectored RSV Vaccine (BLB-201) Low DoseDrug: PlaceboBiological: PIV5-vectored RSV Vaccine (BLB-201) High Dose
- First Posted Date
- 2022-12-19
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Blue Lake Biotechnology Inc.
- Target Recruit Count
- 137
- Registration Number
- NCT05655182
- Locations
- 🇺🇸
Peninsula Research Associates, Rolling Hills Estates, California, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸Velocity Clinical Research, Hastings, Hastings, Nebraska, United States
Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults
Phase 1
Completed
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: CPI-RSV-F Vaccine (BLB-201)
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2023-12-21
- Lead Sponsor
- Blue Lake Biotechnology Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT05281263
- Locations
- 🇺🇸
Coastal Carolina Research Center, North Charleston, South Carolina, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath